References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

nid-1307

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Проблемы иммунодепрессивной терапии гломерулонефритов (Обзор литературы)

Current problems of immunosupression in glomerulonephritis Review

Николаев

А. Ю.

Nikolaev

A. J.

nephrology@mail.ru

Ермоленко

В. М.

Ermolenko

V. M.

noemail@neicon.ru

Захарова

Е. В.

Zakharova

E. V.

noemail@neicon.ru

Кафедра нефрологии и гемодиализа РМАПО, г. МоскваRussian Federation

2008

19062025

1012429

2025

Николаев А.Ю., Ермоленко В.М., Захарова Е.В.

Nikolaev A.J., Ermolenko V.M., Zakharova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/1307

Bыживаемость больных первичным и вторичным хроническим гломерулонефритом (ХГН), а также быстропрогрессирующим гломерулонефритом (БПГН) за последние 20-30 лет увеличилась в 1,5-2 раза [2, 5, 16, 54, 71], однако возможности лечения гломерулонефритов и сегодня ограничены, а безопасность такого лечения недостаточна. Так, при лечении ударными дозами циклофосфана (ЦФ) и глюкокортикостероидов (ГКС) первичного фокального сегментарного гломерулосклероза (ФСГС), мембранозного нефрита (МН), пролиферативного волчаночного гломерулонефрита (ВГН) III и IV класса, в среднем у 50% больных не достигается полная ремиссия, и в последующие 5 лет у половины из них формируется хроническая почечная недостаточность - ХПН [17, 30, 38, 54]. Cреди причин смерти больных гломерулонефритом, длительно леченных неселективными цитостатиками и ГКС, важное место занимают вызванные лекарственным иммунодефицитом тяжелые оппортунистические инфекции, сепсис, онкологические заболевания [71], а также осложнения медикаментозного синдрома Кушинга [4].

хронический гломерулонефритбыстро-прогрессирующий гломерулонефритглюкокортикостероидыциклофосфанциклоспорин Амикофенолатa мофетилантицитокиновые препаратысиролимусвыживаемостьремиссия

References1

Захарова Е.B. ANCA-ассоциированные и криоглобулинемические васкулиты: диагностика и лечение. Нефрология и диализ 2005; 1: 6-25.

Михайлова Н.A., Захарова Е.В., Ипатьева Е.И. Системная красная волчанка с поражением почек: клиническая характеристика и опыт лечения в ГКБ им. С.П. Боткина за период с 1991 по 2001 гг. Нефрология и диализ 2002; 3: 186-191.

Николаев А.Ю. Глава XXVII ( Хроническая почечная недостаточность ) в учебном пособии для послевузовского образования « Нефрология» под ред. Е.М. Шилова. M.: 2007: 541-564.

Тареева И.Е., Шилов Е.М. Глава IX (Гломерулонефриты) в руководстве для врачей «Нефрология» под ред. И.Е. Тареевой. M.: 2000: 188-280.

Тареева И.Е., Шилов Е.М., Краснова Т.Н. Волчаночный нефрит в середине ХХ века и в начале ХХI века. Терапевт. архив 2001; 6: 5-10.

Andoh T.F., Bennet W.M. Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 1998; 7: 265-270.

Alexopoulos E., Cohen J.J. Treatment of primary IgA-nephropathy. Kidney Int 2004; 65: 341-355.

Alexopoulos E., Papagianni A., Tsamelashvili M. Induction and long-term treatment with cyclosporine in membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2006; 21: 3127-3132.

Atta M.G., Gallant J.E., Racusen L.C. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 2809-2813.

Ballow J.E., Austin H.A. Treatment of proliferative lupus nephritis. Am J Kidney Dis 2004; 43: 383-385.

Ballardie F.W. IgA-nephropathy treatment 25 year on: can we halt progression? Nephrol Dial Transplant 2004; 19: 1041-1046.

Ballardi F.W., Roberts I.S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA-nephritis. J Am Soc Nephrol 2002; 13: 142-148.

Benegio R.G., Fuhro R., Wang Z. Sirolimus ameliorates proteinuria-associated tubulo-interstitial inflammation and fibrosis in experimental membranous nephritis. J Am Soc Nephrol 2005; 16: 1878-1879.

Booth A.D., Pusey Ch. D., Jaine D.R. Renal vasculitis - an update in 2004. Nephrol Dial Transplant 2004; 19: 1964-1968.

Booth A.D., Harper L., Hammad I. Prospective study of TNF-alpha blockade with infliximab in ANCA-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-721.

Branten A.J., Reichert L.I., Koene R.A. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Quart J Med 1998; 91: 359-366.

de Buf-Vereijen P.W.G., Wetzel J.F.M. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing activity. Nephrol Dial Transplant 2004; 19: 2036-2043.

de Buf-Vereijken P.W.G., Branten A.J., Wetzels J.F.M. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19: 1142-1148.

de Buf-Vereijen P.W.G., Branten A.J., Wetzels J.F.M. Idiopathic membranous nephropathy: outline and rational treatment strategy. Am J Kidney Dis 2005; 46: 1012-1029.

Cattaneo D., Perico N., Gaspari F. Glucocorticosteroids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-1067.

Cattran D.C., Appel G.B., Herbert L.A. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 1999; 56: 2220-2226.

Cattran D.C., Wang V.V., Appel G.B. Mycophenolate mofetil in the treatment of FSGS. Clin Nephrol 2004; 62: 405-411.

Cayco A.V., Perazella M.A., Hayslett J.P. Renal insufficiency after intravenous Immunoglobulin therapy: a report of two cases and analysis of the literature. J Am Soc Nephrol 1997; 8: 1788-1794.

Сhanders M.O., Gayet S., Schleintz N. Infliximab in the treatment of refractory vasculitis secondary to HCV-associated mixed cryoglobulinaemia. Rheumatol 2004; 24: 532-533.

Cho M.E., Hurley J.K., Kopp J.B. Sirolimus therapy of FSGS is associated with nephrotoxicity. Am J Kidney Dis 2007; 49: 310-317.

Choi M.J., Eustace J.A. Mycophenolate mofetil treatment of primary glomerular diseases. Kidney Int 2002; 62: 1089-1114.

Coombs J.D., Mreich E., Liddle C., Rangan G.K. Rapamycin worsens renal function and intratubular cast formation in protein-overload nephropathy. Kidney Int 2005; 68: 2599-2607.

Daniel C., Renders L., Amann K. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849-2861.

Duncan N., Dhayguide A., Owen J. Treatment of FSGS in adults with tacrolimus therapy. Nephrol Dial Transplant 2004; 19: 3062-3067.

Echrich J.H.H., Geerling C., Zivicgjak M. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and uderdiagnosed. Nephrol Dial Transplant 2007; 22: 2183-2193.

Eisenberger U., Fakhouri F., Vanhille Ph., Beufils H. ANCA-negative pauci-immune vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20: 1392-1399.

Fervenza F.C., Fitzpatrick P.M., Mertz J. Acute sirolimus nephrotoxicity in native kidneys of patients with chronic glomerulonephritis. Neprol Dial Transplant 2004; 19: 1288-1292.

Flanc R., Roberts M.A., Strippoli G.F.M. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.

Fogo A. Progression versus regression of chronic renal disease. Nephrol Dial Transplant 2006; 21: 281-284.

Forman J.P., Brenner B.M. Hypertension and microalbuminuria: the bell tolls for thee. Kidney Int 2006; 69: 22-28.

Goumenos D.S., Tsagalis G., Nahas A.M. Immunosuppressive treatment of idiopathic FSGS: a five-year follow-up study. Nephron 2007; 105: 75-82.

Grinyo J.M. Steroid sparing strategies in renal transplantation. Nephrol Dial Transplant 2005; 20: 2028-2031.

Grootscholten L., Lihtenberg G., Hagen E.C. Azathioprine/methylpred versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-742.

Habashy D., Hodson E.M., Schaefer F. Interventions for steroid-resistant nephrotic syndrome. Pediatr Nephrol 2003; 18: 906-912.

Hirayama K., Kobayashi M., Hashimoto Y. Treatment with purine synthesis inhibitor Mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis 2004; 44: 57-63.

Houssiau F.A., Vasconcelos C., D Cruz D. Euro-Lupus Nephritis Trial, a randomized trial of low dose versus high dose intravenous cyclophosphamide. Arthr Rheum 2002; 46: 2121-2131.

Ito-Ihara T., Ono T., Nogaki F. Clinical efficacy of intravenous Immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron 2006; 102: 35-42.

Jaine D., Rasmussen N., Andrassy K. A randomized trial of maintenance therapy for ANCA-associated vasculitis. New Engl J Med 2003; 349: 36-44.

Jannette J.C. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63: 1164-1177.

Kamar N., Rostaig L., Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69: 436-439.

King D.J., Brunton J., Barr R.D. The influence of corticosteroids on human erythropoiesis. Am J Pediatr Hematol Oncol 1988; 10: 313-315.

Kuzuki M., Asahi K., Asano K. Steroid therapy reduces mesangial matrics accumulation in advanced IgA-nephropathy. Neprol Dial Transplant 2003; 18: 1311-1315.

Laville M., Alamartine E. Treatment options for IgA-nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant 2004; 19: 1947-1951.

Locatelli F., Pozzi C., Andrulli S. IgA-nephritis: ACE inhibitors, steroids, both or neither? Nephrol Dial Transplant 2006; 21: 3357-3361.

Lukas G.M., Eustace J.A., Sozio S., Mentazi E.K. HAART and the incidence of HIV-1-associated nephropathy. AIDS 2004; 18: 541-546.

Markowitz G.S., Radhakrishnan J., D Agati V.D. An overlapping etiology of rapidly progressive glomerulonephritis. Am J Kidney Dis 2004; 43: 388-393.

Meyrier A., Noel L.H., Aurich P., Callard P. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994; 45: 1446-1456.

Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Neprol Dial Transplant 2003; 18 (Suppl. 6): 79-86.

Meyrier A. Nephrotic focal segmental sclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19: 2437-2444.

Morath C., Arns W., Schwenger V. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007; 22 (Suppl. 8): 61-66.

Moroni G., Quanglini S., Galleni B., Ponticelli C. The long-term outcome of 93 patients with proliferative lupus-nephritis. Nephrol. Dial Transplant 2007; 22: 2531-2539.

Myata T., van Ypersele C. Renoprotection of AT1-R blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006; 21: 810-815.

Nagy J., Kovacs T., Wittmann I. Renal protection in IgA-nephropathy requires strict blood pressure control. Nephrol Dial Transplant 2005; 20: 1533-1539.

Nair B. FSGS: cellular variant and beyond. Kidney Int 2006; 70: 1676-1678.

Nakayama M., Katafuchi R., Yanase T. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39: 503-512.

Navarra S.V. Immune therapy in lupus nephritis: what is on the horizon? Nephrol Dial Transplant 2006; 21: 579-581.

Neumann I., Kain R., Redele H., Soleiman A. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 2005; 20: 96-104.

Nichioka Y., Horita Y., Tadokoro M. Mizoribine induced remission of relapsed ANCA-associated vasculitis. Nephrol Dial Transplant 2006; 21: 1087-1088.

Radhakrishnan J., Ginzler J. Mycophenolate - a first-line therapy of severe lupus nephritis. New Engl J Med 2005; 253: 2219-2228.

Rangan G.K., Coombes J.D. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2007; 22: 2175-2182.

Rostoker G., Belghiti D., Ben Maadi A. Long-term cyclosporine A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63: 335-341.

Rump L.C. Secondary rise of albuminuria under AT1-receptor blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 2007; 22: 5-8.

Schmitt W.H., Hagen E., Neumann I. Treatment of refractory Wegener's granulematosis with anti-thymocyte globulin (ATG ): a open study in 15 patients. Kidney Int 2004; 65: 1440-1448.

Seegall L., Covic A., Goldsmith D.J.A. Direct renin inhibitors: the dawn of a new era, or just a variation on a theme. Nephrol Dial Transplant 2007; 22: 2425-2439.

Segarra A., Vila J., Pou L. Combined therapy of tacrolimus and corticosteroids in cyclosporine-resistant or -dependent idiopathic FSGS. Nephrol Dial Transplant 2002; 17: 655-662.

Slot M.C., Tervaert J.W.C., Franssen C.F. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-677.

Stirling C.M. FSGS - does treatment work? Nephron 2006; 104: 83-84.

Stokes M.B., Foster K., Markowitz G.S. Development of glomerulonephritis during anti-TNF-alpha therapy of rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406.

Tumlin J.A., Miller P., Near M. A prospective open-label trial of sirolimus in the treatment of steroid-resistant FSGS. J Am Soc Nephrol 2006; 1: 117-126.

Tune B.M., Mendoza S.A. Treatment of idiopathic nephrotic syndrome: regimes and outcomes in children and adults. J Am Soc Nephrol 1997: 8: 824-832.

Uzu T., Harada T., Sakaguchi M. Glucocorticoid-induced diabetes mellitus: prevalance and risk factors in primary renal disease. Nephron 2007; 105: 54-57.

Wakai K., Kawamura T., Endoh M., Kojima M. A scoring system to predict renal outcome in IgA-nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006; 21: 2800-2808.

Weidner S., Geuss S., Hafezi-Rachti S. АNCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-1411.

Wolf G. Zenon paradox or how much to lower blood pressure for optimal renoprotection. Nephrol Dial Transplant 2005; 20: 2304-2307.

Wong C.F. Rituximab in refractory ANCA-associated vasculitis: what is current evidence? Nephrol Dial Transplant 2007; 22: 32-36.

Zhu B., Chen N., Chen Y., Ren H. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942.

The authors declare that there are no conflicts of interest present.